ory of depression for decades. Numerous candidates have been proposed, from noradrenalin and serotonin abnormalities to cortisol excess, hippocampal insufficiency, and neurotrophic factor. In all cases, results are inconsistent, and where abnormalities are found, they have not been shown to be specific or causal.
For example, contrary to Dr Ravindran and Dr Kennedy's suggestions, the evidence on hippocampal volume is weak. Numerous studies show no difference between subjects with depression and control subjects, and I could not find studies supporting their assertion that duration of untreated illness correlates with volume reduction. In contrast, studies show that duration of treated illness predicts volume reduction. 1, 2 This raises the possibility that drug treatments for depression reduce brain volume in the same fashion as antipsychotics have been shown to do in patients with psychosis. 3 In addition, loss of hippocampal volume is also found in first-episode psychosis 4 and posttraumatic stress disorder 5 and was recently shown in women diagnosed with dissociative identity disorder. 6 Metabolic abnormalities sometimes found in depression are also not specific. For example, acute psychosis is also associated with increased hypothalamopituitary-adrenal axis function. 7 Even if biochemical or structural abnormalities were found to be associated with depression, this would not imply that they were causal. If I experience an adverse event, I will feel sad, and if this emotion is strong enough, there are likely to be associated biochemical changes-but it is the event that has made me sad, not the chemical fluctuations. They are best viewed as an accompaniment, or a biological correlation, of the emotional state.
In my first piece, I concentrated on placebo-controlled studies because it is difficult to show any real-world benefits from the use of antidepressants. In fact, their increased use is associated with increasing prevalence and duration of depressive episodes. The naturalistic Sequenced Treatment Alternatives to Relieve Depression trial found remission rates that are unimpressive in a naturally remitting condition, although the fact that this study did not include a placebo group means this valuable opportunity to evaluate the effectiveness of antidepressants was wasted. 8 The study on absence due to sickness quoted by Ravindran and Kennedy actually found that individuals treated with antidepressants were less likely to return to work than those who were not treated with them (P < 0.001) and had an average of 27 more days on short-term disability benefits. 9 Findings that patients who comply with "optimal " or "adequate" dosages do better than those who do not probably reflect the fact that individuals who comply with any treatment, including placebo, have better outcomes than those who do not. 10 The study of quality of life was a discontinuation study that demonstrated a deterioration in individuals who had improved on drug treatment and were then randomized to placebo. As such, it provides no information on the benefits of antidepressants when they are compared with prospectively started placebo treatment. 11 We do indeed live in an age characterized by an "epidemic of psychological disorders." 12, p 40 However, the mass prescribing of antidepressants and the concomitant message that depression is a brain disease have helped to create this situation, not to improve it. By persuading people that their thoughts and feelings originate from a biological defect, we are preventing them from finding real solutions to the complex problems of modern living.
